Live Breaking News & Updates on Debashis sarker

Stay informed with the latest breaking news from Debashis sarker on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Debashis sarker and stay connected to the pulse of your community

Debashis Sarker | East Asia Forum

Dr Debashis Sarker is an international development professional and researcher who has more than a decade of experience working in multiple sectors such as universities, NGOs, microfinance institutions, investment fund, fintech, disability organisations, research organisations among others in different countries such as Australia, Bangladesh, Belgium, Germany, Kenya. He has a particular research interest in the area of disability inclusive development particularly financial and social inclusion, inclusive education and inclusive employment, and social entrepreneurship for people with disabilities. Currently he is contributing as a researcher for two universities such as University of Sydney, Australia and Torrens University Australia and also working as a guest lecturer at James Cook University, Australia.

Sydney , New-south-wales , Australia , Kenya , Bangladesh , Germany , Belgium , Debashis-sarker , James-cook-university , University-of-sydney , Torrens-university-australia , Crime

Can fintech facilitate financial inclusion of people with disabilities in Bangladesh?

Can fintech facilitate financial inclusion of people with disabilities in Bangladesh?
eastasiaforum.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eastasiaforum.org Daily Mail and Mail on Sunday newspapers.

Australia , Bangladesh , Saudi-arabia , Dhaka , Kenya , Bangladeshi , Debashis-sarker , Mohammad-ponir-hossain , Biman-bangladesh-airlines , Central-bank , Torrens-university-australia , Financial-services

Debashis Sarker | East Asia Forum

Debashis Sarker | East Asia Forum
eastasiaforum.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eastasiaforum.org Daily Mail and Mail on Sunday newspapers.

Australia , Debashis-sarker , Torrens-university-australia , Torrens-university , Bangladesh-disabilities-and-disadvantage , Bangladesh-disadvantage , Bangladesh-government , Bangladesh-popultion , Bangladesh-poverty , Covid-19-bangladesh , Disability-allowances , Disability-allowances-bangladesh

First patient dosed with Sosei's oral immunotherapy drug

The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.

United-kingdom , London , City-of , Cambridge , Cambridgeshire , Bristi-basu , Sosei-heptare , Nigel-blackburn , Matt-barnes , Debashis-sarker , Sosei-heptares , King-college-london

First patient dosed with Sosei's oral immunotherapy drug

The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.

Cambridge , Cambridgeshire , United-kingdom , London , City-of , Sosei-heptare , Bristi-basu , Nigel-blackburn , Sosei-heptares , Matt-barnes , Debashis-sarker , United-kingdom-at-cambridge-university-hospitals

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has been dosed in a Phase I/IIa

United-kingdom , Seoul , Soult-ukpyolsi , South-korea , Japan , Cambridge , Cambridgeshire , London , City-of , Tokyo , Frazer-hall , Shinichiro-nishishita